Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Department of Medicine, Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Subst Use Misuse. 2020;55(13):2205-2212. doi: 10.1080/10826084.2020.1797807. Epub 2020 Aug 7.
Patients with sickle cell disease (SCD) experience high rates of chronic pain, and have a high burden of mental health comorbidities shown to negatively influence health. There is limited research on substance use among individuals with SCD. The aim of this study is to measure the prevalence of substance use in patients with SCD and determine whether psychosocial or clinical risk factors are associated with substance use. This study was conducted as part of an observational study of patients with SCD at two academic medical centers. We asked participants (ages 15 and older) about the lifetime use of heroin, cocaine, amphetamines, and marijuana/cannabis. We measured stigma, depression, urban life stress, pain catastrophizing, and asked about a brief pain inventory. Of 258 participants, 24.9% ( = 71) reported substance use. Marijuana was the most common substance used (22.5%; = 65). The mean depressive score met criteria for positive screen amongst individuals who reported a history of substance use (mean 10.7(5.76)). Adjusting for age, sex, yearly family income, and education level, odds of substance use increased with higher levels of internalized stigma (aOR: 1.38; 95% CI: 1.07, 1.77; = 0.012); higher urban life stress scores (aOR 1.06; 95% CI: 1.01, 1.12; = 0.017) and higher pain catastrophizing scores (aOR: 1.03; 95% CI: 1.01, 1.06; = 0.008). Among individuals with SCD who endorse substance use, there was markedly more stress and distress with higher rates of depression and poorer quality of life. Interventions focusing on improving distress tolerance and coping to not only pain, but also social stressors, might reduce substance use.
患有镰状细胞病 (SCD) 的患者会经历高频率的慢性疼痛,并且存在大量心理健康合并症,这些合并症已被证明会对健康产生负面影响。目前针对 SCD 患者物质使用的研究有限。本研究旨在衡量 SCD 患者物质使用的流行率,并确定是否存在与物质使用相关的心理社会或临床风险因素。本研究是在两家学术医疗中心对 SCD 患者进行的一项观察性研究的一部分。我们询问了参与者(年龄在 15 岁及以上)关于海洛因、可卡因、安非他命和大麻/大麻的终生使用情况。我们测量了耻辱感、抑郁、城市生活压力、疼痛灾难化,并询问了简要疼痛量表。在 258 名参与者中,24.9%( = 71)报告有物质使用史。大麻是最常使用的物质(22.5%; = 65)。报告物质使用史的个体的平均抑郁评分符合阳性筛查标准(平均 10.7(5.76))。调整年龄、性别、年收入和教育水平后,物质使用的可能性随着内化耻辱感的增加而增加(优势比:1.38;95%可信区间:1.07,1.77; = 0.012);城市生活压力评分越高(优势比 1.06;95%可信区间:1.01,1.12; = 0.017)和疼痛灾难化评分越高(优势比:1.03;95%可信区间:1.01,1.06; = 0.008)。在 SCD 患者中,物质使用者报告的压力和困扰明显更大,抑郁发生率更高,生活质量更差。专注于提高痛苦容忍度和应对能力的干预措施,不仅针对疼痛,还针对社会压力源,可能会减少物质使用。